Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1 1

Status

Completed 4

Sponsor Class

OTHER 3INDUSTRY 1

Study Type

Interventional 3Observational 1

Sponsor

Cancer Type

Genitourinary 4Dermatologic 1

Conditions

Prostatic Neoplasms 3Neoplasms 1Castration Resistant Prostate Cancer 1

Interventions

Docetaxel 409pembrolizumab 331Prednisone 289enzalutamide 283Gemcitabine 274Radiotherapy 270Magnetic Resonance Spectroscopy 269Nivolumab 252Abiraterone Acetate 217Cisplatin 212Leuprolide 195Radiosurgery 192Sunitinib 188Carboplatin 161Androgen Antagonists 156bicalutamide 152Specimen Handling 149Goserelin 149Ipilimumab 131Paclitaxel 126acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 122apalutamide 117Cyclophosphamide 117Bevacizumab 116Sorafenib 114Everolimus 111abiraterone 106cabozantinib 104atezolizumab 104Biopsy 101

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Injections, Intramuscular × Genitourinary × Clear all
NCT07161778 2025-09-09

TRICREST

Barts & The London NHS Trust

Phase 2 Completed
55 enrolled
Genitourinary

Castration Resistant Prostate Cancer

NCT00587431 2023-11-07

Docetaxel With Rapid Hormonal Cycling as a Treatment for Patients With Prostate Cancer

Memorial Sloan Kettering Cancer Center

Phase 2 Completed
102 enrolled 8 charts
Genitourinary

Neoplasms, Prostatic Neoplasms

NCT03262103 2022-09-10

Neoadjuvant Hiltonol® (PolyICLC) for Prostate Cancer

Icahn School of Medicine at Mount Sinai

Phase 1 Completed
13 enrolled
Genitourinary

Prostatic Neoplasms

NCT02238366 2019-07-25

CHRONOS3

Ipsen

Completed
368 enrolled
Genitourinary

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡